Navigation Links
Silence Therapeutics Issued Japanese Patent Covering its Core RNA Interference (RNAi) Technology
Date:5/2/2011

LONDON, May 3, 2011 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") announces the issuance of patent 4,705,370, titled "Further Novel Forms of Interfering RNA Molecules," by the Japanese Patent Office.  The issued patent covers aspects of Silence's platform of novel, short interfering RNA (siRNA) molecules containing 2'-O-Methyl structures known as AtuRNAi.  Silence's AtuRNAi molecules offer important advantages over conventional siRNA molecules including increased stability and yield, lower manufacturing costs and the absence of toxic metabolites.  Several therapeutics incorporating the company's AtuRNAi technology are currently being studied in five ongoing clinical trials conducted by Silence and other industry leaders.

"The ability to expand our strong RNAi patent portfolio into a large pharmaceutical market such as Japan represents the latest success in our proactive ongoing intellectual property strategy.  Not only does this milestone offer important protection for our RNAi technology in Japan, but it also provides another critical asset to support our efforts to establish valuable partnerships with leaders in the Japanese pharmaceutical industry," stated Philip Haworth, Ph.D., chief executive officer of Silence Therapeutics.  "We believe that this allowance by the Japanese Patent Office coupled with our broad, global protection offered by our core patents will highlight the value of our RNAi therapeutic technology to those Japanese companies with an interest in this exciting area of medicine."

Silence Therapeutics is executing a proactive strategy to continue to build and strengthen a global, diverse and competitive intellectual property portfolio that provides the Company and its partners with a strong proprietary position in the RNAi therapeutics space.  The Company believes that it will continue to make significant progress in these efforts as it expects additional RNAi patents to be issued during 2011.  At present, Silence's global patent portfolio contains issued patents and pending applications covering strategic areas of RNAi therapeutic development including multiple proprietary siRNA delivery technologies, potent siRNA sequences specific for high-value disease targets and key RNAi sequence and chemical modifications.

Notes for editors

About Silence Therapeutics plc (www.silence-therapeutics.com)

Silence Therapeutics plc (AIM: SLN) is a leading global biotechnology company dedicated to the discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases.  The company possesses multiple proprietary short interfering RNA (siRNA) delivery technology platforms including AtuPLEX, a system that enables the functional delivery of siRNA molecules to targeted diseased tissues and cells, while increasing their bioavailability and intracellular uptake. Additionally, the company has a platform of novel siRNA molecules, AtuRNAi, which provide a number of advantages over conventional siRNA molecules, including reduced cytokine induction and decreased manufacturing costs.  Silence's unique RNAi assets also include structural features for a next generation of RNAi molecules and additional proprietary siRNA sequences against more than 50 highly valued oncology and other disease targets.

The Company's lead internal drug candidate is Atu027, a liposomal AtuRNAi formulation in clinical development for systemic cancer indications and one of the most clinically advanced RNAi therapeutics in the area of oncology. Silence is currently conducting an open-label, single-centre, dose-escalation Phase I study with Atu027 in patients with advanced solid tumors involving single, as well as, repeated intravenous administration. The study is expected to be completed in the second half of 2011.

The Company's RNAi therapeutic platform has received key validation through multiple partnerships with pharmaceutical companies including AstraZeneca, Dainippon Sumitomo, Pfizer, and Quark. Silence is actively pursuing the establishment of additional partnerships.

Forward-Looking Statements

This press release includes forward-looking statements that are subject to risks, uncertainties and other factors. These risks and uncertainties could cause actual results to differ materially from those referred to in the forward-looking statements. All forward-looking statements are based on information currently available to Silence Therapeutics and Silence Therapeutics assumes no obligation to update any such forward-looking statements.


'/>"/>
SOURCE Silence Therapeutics plc
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Silence Therapeutics Lead RNA Interference Therapeutic Prevents Spread of Cancer to Lungs
2. Silence Therapeutics Receives Comprehensive Protection for RNAi Structural Modification Technology in Single European Patent
3. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
4. Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
5. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
6. Silence Therapeutics Appoints New Vice President of Research
7. Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference
8. National Ovarian Cancer Coalition and PureOlogy to Host First Annual NOCC and PureOlogys Walk to Break the Silence on Ovarian Cancer
9. Cell Therapeutics Retires 7.5% Convertible Senior Notes
10. Talecris Biotherapeutics Announces First Quarter 2011 Results
11. Nektar Therapeutics Reports First Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... , April 29, 2016 ... the latest update to its industry-leading treatment planning software, ... that Monaco version 5.11 provides ... now attain calculation speeds up to four times faster ... . With the industry,s gold standard Monte ...
(Date:4/28/2016)... ... April 28, 2016 , ... As ... recruiting top industry experts, and expanding its LATAM network and logistics capabilities. ... clients to manage their clinical trial projects. , The expansion will provide unmatched ...
(Date:4/27/2016)... ... April 27, 2016 , ... Most consumers engage ... fingerprint recognition for secure access, voice recognition for hands-free communication, and facial recognition ... interacting with biometrics technology today. But if they asked Joey Pritikin, Vice ...
(Date:4/27/2016)... ... April 27, 2016 , ... ... to its Scientific Advisory Board. Dr. Lamka will assist PathSensors in expanding the ... , PathSensors deploys the CANARY® test platform for the detection of harmful ...
Breaking Biology Technology:
(Date:3/11/2016)... PUNE, India , March 11, 2016 ... to a new market research report "Image Recognition Market ... by Application (Marketing and Advertising), by Deployment Type (On-Premises ... Global Forecast To 2022", published by MarketsandMarkets, the global ... in 2015 to USD 29.98 Billion by 2020, at ...
(Date:3/9/2016)... Fla. , March 9, 2016  Crossmatch ... authentication and enrollment solutions, today announced the addition ... ® Altus multi-factor authentication platform. New ... InfoSec managers to step-up security where it,s needed ... Washington, DC . --> ...
(Date:3/2/2016)... March 2, 2016 ... addition of the  "Global Biometrics Market in ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , Global biometrics ... at a CAGR of around 27%   ... has announced the addition of the  "Global ...
Breaking Biology News(10 mins):